##### Table of Contents



FORM 10-K/A-1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

(Mark One)

|      |  |                                                                                         
|----- |  | ----------------------------------------------------------------------------------------
|[X]   |  | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934    
|      |  |                                                                                         
|      |  | For the fiscal year ended December 31, 2001                                             
|      |  |                                                                                         
|      |  | OR                                                                                      
|      |  |                                                                                         
|[   ] |  | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
|      |  |                                                                                         
|      |  | For the transition period from  to                                                      

Commission File No. 000-30549

GENOMIC SOLUTIONS INC.
(Exact name of registrant as specified in its charter)

|                                         |  |                                    
|---------------------------------------- |  | -----------------------------------
|State of Delaware
State of Incorporation |  | 38-3383038
I.R.S. Employer I.D. No.

4355 Varsity Drive
Ann Arbor, Michigan 48108
(734) 975-4800
(Address of principal executive offices and telephone number)

Securities Registered Pursuant to Section 12(b) of the Act:None

Securities Registered Pursuant to Section 12(g) of the Act:Common Stock, Par Value $.001 Per Share(see explanatory note)

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of Registrants knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to
this Form 10-K. [   ]

Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.

Yes X No

As of April 25, 2002, the aggregate market value of the Registrants common
stock held by non-affiliates of the Registrant was approximately $24,094,709,
determined in accordance with the highest price at which the stock was sold on
such date as reported by the Nasdaq National Market.

As of April 25, 2002, there were 33,095,117 shares of the Registrants common stock issued and outstanding.

EXPLANATORY NOTE: This Amendment No. 1 to the Registrants Annual Report on
Form 10-K for the fiscal year ended December 31, 2001 (the Form 10-K) is
filed to add certain exhibits under Part IV, Item 14.





---

TABLE OF CONTENTS



|                                           |                                                                           |  |  |  |  |  |  | 
|------------------------------------------ | ------------------------------------------------------------------------- |  |  |  |  |  |  | 
|                                           | ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K:
|SIGNATURES                                
|EXHIBIT INDEX                             
|EX-23.1 Consent of Arthur Andersen LLP    
|EX-99.1 Information Required by Form 11-K 
|EX-99.2 Letter from Genomic Solutions Inc.



---



##### Table of Contents






PART IV

ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K:

(3) Exhibits:

|     |  |   |  |                                                                                                               
|---- |  | - |  | --------------------------------------------------------------------------------------------------------------
|23.1 |  |  |  | Consent of Arthur Andersen LLP, Independent Public Accountants                                                
|     |  |   |  |                                                                                                               
|99.1 |  |  |  | Information required by Form 11-K with respect to the Genomic Solutions
Inc. 2000 Employee Stock Purchase Plan
|     |  |   |  |                                                                                                               
|99.2 |  |  |  | Letter from
Genomic Solutions Inc. dated April 29, 2002 regarding Arthur Andersen
LLP                         

2



---



##### Table of Contents






SIGNATURES

The undersigned registrant hereby amends the following items, financial
statements and exhibits of its Annual Report for its fiscal year ended December
31, 2001 on Form 10-K as set forth in the pages attached hereto:

To file as Exhibit 99.1 the Information, Financial Statements and Exhibits
required by Form 11-K for the Genomic Solutions Inc. 2000 Employee Stock
Purchase Plan.

Pursuant to the requirements of Section 13 or 15(d) of the Security
Exchange Act of 1934, the Registrant has duly caused this Form 10-K/A-1 report
to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: April 29, 2002

| |  |                        |  |                                                                                                                                                     
| |  | ---------------------- |  | ----------------------------------------------------------------------------------------------------------------------------------------------------
| |  | GENOMIC SOLUTIONS INC.
| |  |                        |  |                                                                                                                                                     
| |  | By:                    |  | /s/ Jeffrey S. Williams                                                                                                                             
| |  |                        |  |                                                                                                                                                     
| |  |                        |  | Jeffrey S. Williams, President and
Chief Executive Officer                                                                                          
| |  |                        |  |                                                                                                                                                     
| |  | By:                    |  | /s/ Steven J. Richvalsky                                                                                                                            
| |  |                        |  |                                                                                                                                                     
| |  |                        |  | Steven J. Richvalsky, Chief
Financial Officer, Executive
Vice President and Treasurer
(Principle Financial Officer and
Principle Accounting Officer)

3



---



##### Table of Contents



Pursuant to the requirements of the Securities Exchange Act of 1934, this
Annual Report on Form 10-K has been signed by the following persons on behalf
of the registrant and in the capacities and on the dates indicated.

|                                                 |  |                                                 |  |               
|------------------------------------------------ |  | ----------------------------------------------- |  | --------------
|Name                                             |  | Title                                           |  | Date          
|                                                 |  |                                                 |  |               
|/s/ Jeffrey S. WilliamsJeffrey S. Williams       |  | President, Chief Executive
Officer and Director |  | April 29, 2002
|                                                
|                                                 |  |                                                 |  |               
|                                                
|/s/ Robert G. SheplerRobert G. Shepler           |  | Chairman of the Board of
Directors              |  | April 29, 2002
|                                                
|                                                 |  |                                                 |  |               
|                                                
|/s/ J. Matthew MackowskiJ. Matthew Mackowski     |  | Director                                        |  | April 29, 2002
|                                                
|                                                 |  |                                                 |  |               
|                                                
|/s/ Daniel J. MitchellDaniel J. Mitchell         |  | Director                                        |  | April 29, 2002
|                                                
|                                                 |  |                                                 |  |               
|                                                
|/s/ Damion E. Wicker, M.D.Damion E. Wicker, M.D. |  | Director                                        |  | April 29, 2002
|                                                
|                                                 |  |                                                 |  |               
|                                                
|/s/ Thomas C. TisoneThomas C. Tisone, Ph.D.      |  | Director                                        |  | April 29, 2002

4



---



##### Table of Contents






EXHIBIT INDEX

|            |  |   |  |                                                                                                               
|----------- |  | - |  | --------------------------------------------------------------------------------------------------------------
|Exhibit No. |  |   |  | Description                                                                                                   
|            |  |   |  |                                                                                                               
|23.1        |  |  |  | Consent of Arthur Andersen LLP, Independent Public
Accountants                                                
|            |  |   |  |                                                                                                               
|99.1        |  |  |  | Information required by Form 11-K with respect to the
Genomic Solutions Inc. 2000 Employee Stock Purchase Plan
|            |  |   |  |                                                                                                               
|99.2        |  |  |  | Letter from
Genomic Solutions Inc. dated April 29, 2002 regarding Arthur Andersen
LLP                         

5